Hamad Medical Corporation (HMC) has unveiled two innovative treatment options for patients with treatment-resistant depression at the Mental Health Service of Mesaieed General Hospital: Esketamine and Transcranial Magnetic Stimulation (TMS).
Esketamine, a nasal spray, offers new hope for individuals who have struggled with conventional treatments, according to Dr. Ovais Wadoo, senior consultant and clinical lead for Neuromodulation Services at HMC. This FDA-approved treatment is administered in a clinical setting under professional supervision and is particularly effective for those who have not responded to other antidepressants.
In addition, HMC will soon provide TMS therapy, which uses magnetic pulses to stimulate specific brain areas linked to mood regulation. “TMS is a non-invasive alternative for patients who either cannot tolerate the side effects of traditional medications or have found them ineffective,” Dr. Wadoo noted.
Both Esketamine and TMS have demonstrated significant efficacy in reducing symptoms of depression, with Esketamine offering rapid relief for many patients and TMS resulting in lasting improvements in mood and functionality. These treatments aim to enhance the quality of life for individuals who have had limited success with traditional therapies.
The introduction of these advanced mental health services aligns with Qatar’s National Vision 2030 and the National Health Strategy 2024 to 2030, which emphasize the importance of mental health as a vital aspect of overall well-being. By expanding access to these innovative therapies, HMC is dedicated to fostering a healthier society and supporting the nation’s goal of improving healthcare services.
